Titre :	An estimate of global for paziquantel within schistoxomiasis control programmes
Type de document :	texte imprimé
Auteurs :	Utroska, J. A. ; Chen, M. G. ; Dixon, H.
Mention d'édition :	World Health Organization
Editeur :	World Health organization
Année de publication :	[sd]
ISBN/ISSN/EAN :	CI-07088
Note générale :	This document is a attemp to provide an analytical framework for public health planners and administrators of endemic countries. 1) to reassess estimates of the prevalence of schistoxomiasis, 2) to determine the quantity of proziquantel needed to treat all infected persons with a single dose and, 3) to propose a basis for longitudinal calcultions of praziquantel needs in endemic countries. It emphasizes the limitations of current methodology and available data to calculate both the prevalence of schistoxomiasis and the requisements of a single drug such as praziquantel.
Langues :	Anglais (eng)
Mots-clés :	Medicament  Population  Morbidité  Epidemiologie  Politique sanitaire  Recherche Medicale  Programme contrôle  Schistoxomiase  Chimittérapie  Schistosome
Index. décimale :	614.4 Incidence des maladies et mesures de prévention : classer ici l'épidémiologie
Résumé :	This document is a attemp to provide an analytical framework for public health planners and administrators of endemic countries. 1) to reassess estimates of the prevalence of schistoxomiasis, 2) to determine the quantity of proziquantel needed to treat all infected persons with a single dose and, 3) to propose a basis for longitudinal calcultions of praziquantel needs in endemic countries. It emphasizes the limitations of current methodology and available data to calculate both the prevalence of schistoxomiasis and the requisements of a single drug such as praziquantel.
Note de contenu :	This document is a attemp to provide an analytical framework for public health planners and administrators of endemic countries. 1) to reassess estimates of the prevalence of schistoxomiasis, 2) to determine the quantity of proziquantel needed to treat all infected persons with a single dose and, 3) to propose a basis for longitudinal calcultions of praziquantel needs in endemic countries. It emphasizes the limitations of current methodology and available data to calculate both the prevalence of schistoxomiasis and the requisements of a single drug such as praziquantel.

An estimate of global for paziquantel within schistoxomiasis control programmes [texte imprimé] / Utroska, J. A. ; Chen, M. G. ; Dixon, H.  . -  World Health Organization . - World Health organization, [sd].
ISSN : CI-07088
This document is a attemp to provide an analytical framework for public health planners and administrators of endemic countries. 1) to reassess estimates of the prevalence of schistoxomiasis, 2) to determine the quantity of proziquantel needed to treat all infected persons with a single dose and, 3) to propose a basis for longitudinal calcultions of praziquantel needs in endemic countries. It emphasizes the limitations of current methodology and available data to calculate both the prevalence of schistoxomiasis and the requisements of a single drug such as praziquantel.
Langues : Anglais (eng)

Mots-clés :	Medicament  Population  Morbidité  Epidemiologie  Politique sanitaire  Recherche Medicale  Programme contrôle  Schistoxomiase  Chimittérapie  Schistosome
Index. décimale :	614.4 Incidence des maladies et mesures de prévention : classer ici l'épidémiologie
Résumé :	This document is a attemp to provide an analytical framework for public health planners and administrators of endemic countries. 1) to reassess estimates of the prevalence of schistoxomiasis, 2) to determine the quantity of proziquantel needed to treat all infected persons with a single dose and, 3) to propose a basis for longitudinal calcultions of praziquantel needs in endemic countries. It emphasizes the limitations of current methodology and available data to calculate both the prevalence of schistoxomiasis and the requisements of a single drug such as praziquantel.
Note de contenu :	This document is a attemp to provide an analytical framework for public health planners and administrators of endemic countries. 1) to reassess estimates of the prevalence of schistoxomiasis, 2) to determine the quantity of proziquantel needed to treat all infected persons with a single dose and, 3) to propose a basis for longitudinal calcultions of praziquantel needs in endemic countries. It emphasizes the limitations of current methodology and available data to calculate both the prevalence of schistoxomiasis and the requisements of a single drug such as praziquantel.